Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations

NCT02450591 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

4

Enrollment

OTHER

Sponsor class

Conditions

Oligometastatic Lung Adenocarcinoma

Interventions

DRUG: Erlotinib
OTHER: Local Therapies

Sponsor

Memorial Sloan Kettering Cancer Center